IMAGE: D. Ross Camidge, M.D., Ph.D., and colleagues show 51 percent reduction in risk of death over course of phase III ALTA-1 trial with brigatinib compared with cirzotinib. view more
Credit: University of Colorado Cancer Center
Results of a 275-patient, multi-national phase III clinical trial known as ALTA-1L published today in the New England Journal of Medicine and presented concurrently in the press program at the International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer 2018 argue for brigatinib as a first-line treatment option for advanced ALK-positive non-small cell lung cancer.
ALTA-1L compared the benefits of crizotinib, the first licensed ALK inhibitor, with brigatinib, a next generation ALK inhibitor, which already has proven activity when given to a patient after they have progressed on crizotinib. The primary endpoint of the study was progression free survival (PFS), the time that a patient can live with a cancer without it getting worse, assessed by an independent review committee. Patients had to have never received ALK inhibitor therapy before.
The first preplanned interim analysis of trial data was triggered by the 99th progression event, which occurred after a median follow-up in the two arms of only 9-11
Article originally posted at